Ainos, Inc.

What they do

Ainos operates two platforms: AI Nose, an AI-driven electronic olfaction system that converts volatile organic compound signals into machine-readable 'Smell ID' data, and VELDONA, a low-dose oral interferon platform targeting rare, autoimmune, and infectious disease indications. AI Nose is being deployed in semiconductor manufacturing, robotics, and smart manufacturing environments, with additional exploratory healthcare-adjacent applications. Revenue has been minimal, with small amounts from AI Nose-related products and pet supplements.

Revenue drivers

• AI Nose hardware and service — Targeted revenue from sales of AI Nose hardware systems and recurring service-based offerings ('SmellTech-As-A-Service'). Generated $123,360 in 2025, up from nil in 2024, but still minimal.
• Pet supplements (Veldona Pet) — Limited sales of Veldona Pet supplement in Taiwan. Revenue was $797 in 2025 and $20,321 in 2024.
• VELDONA therapeutic out-licensing — Potential future out-licensing of VELDONA candidates for oral warts, Sjögren's syndrome, and feline chronic gingivostomatitis. No revenue recorded to date.

Recent performance

For the second quarter ended June 30, 2026, revenue was $152, a decline from $11,120 in the prior quarter and $2,167 in the quarter ended September 30, 2025. For full-year 2025, revenue was $124,157 with an operating loss of $13,990,408, and net loss of $14.8 million. As of June 30, 2026, the company had cash of $1.4 million, total assets of $19.6 million, total liabilities of $16.3 million, and stockholders' equity of $3.3 million. The company has a history of operating losses and an accumulated deficit of $67.5 million as of December 31, 2025.

Strategy

Management's primary focus is commercializing AI Nose through partner-led deployments, particularly in semiconductor manufacturing, robotics, and smart manufacturing. The strategy includes expanding the Smell ID dataset and improving the smell language model through real-world data, while also pursuing channel and integration partnerships. VELDONA is being managed selectively and capital-efficiently, with clinical activities in Taiwan and pursuit of out-licensing opportunities. The company emphasizes disciplined capital allocation and operational efficiency.

Risks

• Limited revenue and recurring losses — Revenue is negligible, and the company has incurred significant operating losses each year, with accumulated deficit exceeding $67 million.
• Dependence on AI Nose commercial success — Future viability hinges on successful commercialization of AI Nose, which is still in early stages with no guarantee of broad market adoption.
• Cash and capital needs — With only $1.4 million in cash as of June 30, 2026, the company may need additional capital to fund operations and meet obligations.
• Regulatory and clinical uncertainty for VELDONA — VELDONA clinical programs are subject to regulatory review and study progress, and no approval or commercialization is assured.

Outlook

Management expects to continue advancing AI Nose deployments and validation activities across semiconductor manufacturing, industrial infrastructure, healthcare, and robotics environments. The company believes these efforts will support broader revenue generation in the second half of 2026. VELDONA clinical and partnering milestones are expected in the 2026-2027 timeframe, subject to regulatory and study progress.